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Supplementary Figure 1 Manhattan plots of population specific meta-analyses 
Panel a. Central Asian preeclampsia offspring, b. European preeclampsia offspring, c. Central Asian 























Supplementary Figure 2 Power to detect genome-wide significant association using the current 
meta-analyses 
The plots show allelic odds ratio (OR) required for 80% power to detect association to preeclampsia 
at genome-wide significance (P < 4 × 10−9 after adjusting for 12 million variants tested) in meta-
analysis of offspring or maternal subjects from Europe, Central Asia or Europe and Central Asia 
combined. Results are shown for a causal SNP with minor allele frequency (MAF) in the range of 0.01-
0.5.  
a. Offspring meta-analyses. Effective sample size for the Central-Asian, European and Combined 
meta-analysis is 2,064, 7,259 and 9,323 cases respectively and an equal number of controls. In 
the combined analysis we have 80% power to detect an OR > 1.15 at MAF = 0.5. 
b. Maternal meta-analyses. Effective sample size for the Central-Asian, European and Combined 
meta-analysis is 2,137, 10,255 and 12,392 cases respectively and an equal number of controls. In 





































































Supplementary Figure 3 Forest plots of variants associating with preeclampsia through fetal or 
maternal genome. 
Variant name followed by risk allele and locus name are presented at the top. Name of study, 
number of cases and controls, odds ratio (OR) and P-value are indicated. For each variant results are 
presented for each GWAS dataset and each follow-up dataset. META indicates meta-analysis results 
for GWAS datasets, follow-up datasets and Combined indicates the combined results for the GWAS 
and follow-up datasets. The first plot is based on association in preeclampsia offspring while the 
other five are based on association in maternal preeclampsia. Stars indicate that a proxy marker was 
used, for details see footnote in Supplementary Table 2 (offspring variants) and footnotes in 
Supplementary Data 2 (maternal variants). a. Variants with genome-wide significant association, b. 
Variants at loci validated through association with BP. Individual cohort P-values are obtained from 
logistic regression of case status on genotype count adjusted for covariates (see Methods). META and 
Combined P-values are obtained from fixed-effect meta-analysis of effects and P-values, adjusted for 














Supplementary Figure 4 Locus plots for variants associating with preeclampsia through fetal or 
maternal genome. 
P values (-log10) of SNP associations in the meta-analysis are plotted against their chromosomal 
positions (NCBI Build 37 coordinates). Index variant is denoted by a purple diamond; other variants 
are colored to reflect their correlation with the index variant. Known genes in the region are shown 
underneath the plot. Secondary signals at the FLT1/13q12 locus: rs9508092 is shown after 
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Supplementary Figure 5 Comparison of effect estimates for BP risk variants in preeclampsia and BP traits 
The plots show variants reported to be associated with BP traits (Diastolic BP, Systolic BP or Pulse pressure) [Evangelou, E. et al. PMID: 30224653] 
and also highlight the five variants associated with preeclampsia in this study. Effect in meta-analysis of Icelandic and UK data sets of the allele 
associated with increased BP on a) Diastolic BP, b) Systolic BP and c) Hypertension (x-axis) vs. effect in European meta-analysis on maternal 
preeclampsia (y-axis). Crosses indicate 95% confidence intervals. Dots show only those variants with P < 0.05 for each BP trait and with MAF > 5% 
in our preeclampsia meta-analysis. Green dots and their corresponding rs ID denote the four variants reported here that associate with 
preeclampsia through BP. The fifth green dot denotes the FTO variant rs1421085 which is absent from the BP list used here which is based on 
BMI adjusted BP analysis. Blue dots denote other variants for which P < 0.05 for preeclampsia. Black dots denote variants with P ≥ 0.05 for 
preeclampsia. The blood pressure and hypertension data are based on combined analyses of males and females in the Icelandic and UK datasets. 




Supplementary Figure 6.  Ancestry Principal Components of Central Asia compared to European and 
Asian 1000 Genomes Populations 
 
The plot shows that the Kazakh and Uzbek populations in the context of European and Asian 1000 
genomes populations.  Both the Central Asian populations are on a cline between East Asia and Europe 
with Uzbekistan exhibiting a greater affinity with Europe and South Asia. The number of subjects in each 







Supplementary Figure 7: Imputation performance for Chromosome 1 vs Central Asia MAF 
 
The Minor Allele Frequency (MAF) is as calculated in the combined Central Asian WGS samples. The 




























Supplementary Figure 9: Proportion of recovered 1000 Genomes SNPs versus Central Asia GATK 
Variant Calling Threshold (VQSLOD) 
 
The plots show that variants that are common (maf > 10%) in all 1000 genomes regional populations and 
in the 1000 genomes accessible genomic regions are reliably discovered in our dataset. The 1000 
Genomes VQSLOD was downloaded from 
ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/phase1/analysis_results/consensus_call_sets/snps/ALL.wgs.LC
_VQSR2b_EX_ILLUMINA_EX_SOLID_union.phase1.snps.lowcov_plus_exome.sites.vcf.gz. Accessibility 








Supplementary Figure 10.  Efficacy of Genotype Refinement 
 





Supplementary Figure 11: Per Sample Concordance vs Per Sample Coverage 
 
The plot shows that the concordance improves markedly with sample coverage. The concordance with 






Supplementary Figure 12: Imputation performance for Chromosome 1 vs Europe MAF 
 
The Minor Allele Frequency (MAF) is as calculated in the 1000 Genomes Phase 3 European samples. The 





Supplementary Figure 13: Imputation performance for Chromosome 1 vs East Asia MAF  
 
The Minor Allele Frequency (MAF) is as calculated in the 1000 Genomes Phase 3 East Asian samples. The 








Supplementary Figure 14: Imputation performance for Chromosome 1 vs South Asia MAF  
The Minor Allele Frequency (MAF) is as calculated in the 1000 Genomes Phase 3 Southern Asian samples. 




Supplementary Table 1 | Studies included in meta-analyses, follow-up and downstream analyses 
Study       





controls Population Controls Genotyping platform 
Imputation 
reference set 
GOPEC 1,004 5,286 UK Population 
Cases: Illumina OmniExpress; 
Controls: Illumina 1M 
1000G P1 
deCODE 2,221 360,005 Iceland Population Illumina (various) deCODE WGS 
ALSPAC 146 6,130 UK Non PE offspring Illumina HumanHap550 1000G P1 
MoBa 1,046 961 Norway Non PE offspring Illumina HumanCoreExome-12 1000G P3 
SSI 213 963 Denmark Population Illumina MEGAEX HRC 
Total Europe 4,630 373,345     
Kazakh 1 789 795 Kazakhstan Non PE mothers Illumina 2.5-8 1000G P3+ CA WGS 
Kazakh 2 542 349 Kazakhstan Non PE mothers Illumina OmniExpress 1000G P3+ CA WGS 
Uzbek 814 883 Uzbekistan Non PE mothers Illumina 2.5-8 1000G P3+ CA WGS 
Total Central Asia 2,145 2,027     
Europe + Central Asia 6,775 375,372         
Maternal meta-analysis       
GOPEC 1,875 5,088 UK Population 
Cases: Illumina 670; Controls: 
Illumina 1M 1000G P1 
deCODE 2,453 134,837 Iceland Female Population Illumina (various) deCODE WGS 
ALSPAC 150 6,161 UK Non PE mothers Illumina human660W 1000G P1 
MoBa 1,469 954 Norway Non PE mothers Illumina HumanCoreExome-12 1000G P3 
SSI 872 815 Denmark Non PE mothers Illumina MEGAEX HRC 
FINRISK 400 7,805 Finland Non PE mothers Illumina HumanCoreExome-12 Finnish WGS/WES 
Total Europe 7,219 155,660     
Kazakh 1 846 814 Kazakhstan Non PE mothers Illumina 2.5-8 1000G P3+ CA WGS 
Kazakh 2 640 361 Kazakhstan Non PE mothers Illumina OmniExpress 1000G P3+ CA WGS 
Uzbek 810 884 Uzbekistan Non PE mothers Illumina 2.5-8 1000G P3+ CA WGS 
Total Central Asia 2,296 2,059     
Europe + Central Asia 9,515 157,719         
Follow up       
Offspring analysis       
FINNPEC 580 760 Finland Non PE offspring TaqMan  
Kazakh 3 452 361 Kazakhstan Non PE mothers Illumina Infinium GSA 1000G P3+ CA WGS 
Total offspring 1,032  1,121          
Maternal analysis       
FINNPEC 678 700 Finland Non PE mothers Sequenom iPLEX  
DNBC 335 1,054 Denmark Non PE mothers Centaurus (Nanogen)  
HUNT 1,030 4,264 Norway Female Population Illumina (various) HRC+ HUNT WGS 
Kazakh 3 592 361 Kazakhstan Non PE mothers Illumina Infinium GSA 1000G P3+ CA WGS 
Total maternal 2,635 6,379         
Gestational hypertension       
Offspring analysis       
deCODE 3,185 375,701 Iceland Population Illumina (various) deCODE WGS 
ALSPAC 1,090 6,039 UK 
Non PE/GH 
offspring Illumina HumanHap550 1000G P1 
Total offspring gestational 
hypertension 4,275 381,740         
Maternal analysis       
deCODE 2,380 133,925 Iceland Female Population Illumina (various) deCODE WGS 
ALSPAC 1,048 6,162 UK 
Non PE/GH 
mothers Illumina HumanHap550 HRC  
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Total maternal gestational 




Supplementary Table 2 |Follow up of variants with P < 1E-6 in the offspring meta-analysis            
            Discovery 
FINNPEC                             
N=580 cases/760 ctrl 
Kazakh 3                                         
N=452 cases/361 ctrl 
Combined discovery and 
follow-up 
  




allele RAF OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value OR (95%CI) P-value 
Annotated 
gene/cytoband 
rs4769612a 13 29,138,498 c t 0.52 1.17 (1.12-1.23) 3.0E-11 1.27 (1.09-1.49) 2.5E-03 1.27 (1.03-1.56) 0.028 1.19 (1.13-1.24) 4.3E-14 FLT1/13q12 
rs11614652 12 26,958,002 g c 0.21 1.18 (1.10-1.25) 2.2E-07   1.12 (0.81-1.54) 0.50 1.18 (1.10-1.23) 1.7E-07 ITPR2/12p11 
rs5866671 5 24,557,312 t ta 0.20 1.18 (1.11-1.25) 1.3E-07   1.02 (0.76-1.37) 0.88 1.17 (1.10-1.25) 2.0E-07 CDH10/5p14 
rs75293382 2 228,510,336 c t 0.06 1.33 (1.19-1.49) 6.2E-07     1.05 (0.74-1.47) 0.80 1.30 (1.18-1.45) 1.4E-06 C2orf83/2q36 
Positions are based on Human genome version 19 (hg19), build 37. Chr, chromosome; RAF, risk allele frequency; OR, odds ratio; CI, confidence interval.   
aFINNPEC: rs4769613 (r2 = 1 with rs4769612)           
 
 
Supplementary Table 3 |Conditional analysis chr13 locus      
        Discovery Conditioned on rs4769612 
Conditioned on             
rs4769612 and rs9508092 
Variant Chr Position RA/OA RAFEUR RAFCA OR (95%CI) P OR (95%CI) P OR (95%CI) P 
rs4769612 13 29138498 C/T 0.52 0.47 1.17 (1.12-1.23) 3.0E-11     
rs9508092 13 29186162 T/C 0.77 0.74 1.19 (1.12-1.26) 1.6E-08 1.20 (1.13-1.27) 3.0E-09   
rs71433277 13 29218967 T/C 0.15 0.25 1.19 (1.12-1.26) 1.7E-08     1.15 (1.08-1.22) 6.6E-06 
Positions are based on Human genome version 19 (hg19), build 37.  Chr, chromosome; RA, risk allele; OA, other allele; RAFEUR, risk allele frequency in European 




Supplementary Table 4 | Correlation (r2) between variants at the chr13 FLT1 locus reported in 
this study and previous report [PMID: 28628106] 
Variant rs149427560 rs4769612 rs4769613 rs9508092 rs71433277 rs12050029 
rs149427560 1 0 0 0.01 0 0 
rs4769612 0 1 0.99 0.00 0.00 0.00 
rs4769613 0 0.99 1 0.00 0.00 0.00 
rs9508092 0.01 0.00 0.00 1 0.01 0.02 
rs71433277 0 0.00 0.00 0.01 1 0.97 
rs12050029 0 0.00 0.00 0.02 0.97 1 
 
 
Supplementary Table 5 | Correlation in European and Kazakh samples between variants with the 
lowest P-value in the maternal preeclampsia meta-analysis and blood pressure variants reported in 














rs1918975 3 169179876 rs419076 169100886 0.36 0.12 
rs1458038 4 81164723 rs16998073 81184341 0.94 0.83 
rs10774624 12 111833788 rs3184504 111884608 0.88 0.97 













Null hypothesis probability of 
observing [C] or more 
Concordant Variantsa 
European PE mothers 892 588 P < 1.2E-21 
Central Asian PE mothers  883 504 P < 2.9E-05 
European and Central Asian PE mothers 891 591 P < 1.1E-22 
   
   
European GH mothers 888 564 P < 7.1E-16 
892 BP variants omit our genome-wide significant PE variants from list of 896 known BP variants (Supplementary 
Table 18 in Evangelou et al. 2018 [PMID: 30224653]) 
aNull hypothesis is none of 892 variants are associated with PE/GH; null rejected as improbable by very low p-
values as calculated by two-tail binomial test of proportion. 





Supplementary Table 7 | Results for associated variants in offspring and maternal and discovery meta-
analyses 




analysis   
Variant Chr Position RA OA RAF P-value OR (95%CI) P-value OR (95%CI) 
Annotated 
gene/cytoband 
Fetal            
rs4769612 13 29,138,498 c t 0.52 3.0E-11 1.17 (1.12-1.23) 8.9E-07 1.10 (1.06-1.14) FLT1/13q12 
Maternal            
rs1918975 3 169,179,876 t c 0.60 0.045 1.05 (1.00-1.10) 2.5E-08 1.12 (1.07-1.16) MECOM/3q26 
rs1458038 4 81,164,723 t c 0.33 6.0E-05 1.11 (1.05-1.16) 4.2E-08 1.12 (1.07-1.16) FGF5/4q21 
rs10774624 12 111,833,788 g a 0.40 0.28 1.03 (0.98-1.08) 7.0E-08 1.12 (1.07-1.16) SH2B3/12q24 
rs1421085 16 53,800,954 c t 0.39 1.4E-03 1.08 (1.03-1.14) 2.0E-09 1.13 (1.08-1.17) FTO/16q12 
rs259983 20 57,735,457 c a 0.14 9.4E-03 1.10 (1.02-1.18) 2.2E-07 1.15 (1.09-1.22) ZNF831/20q13 
Positions are based on Human genome version 19 (hg19), build 37. Chr, chromosome; RA, risk allele; OA, other allele; RAF, risk allele 
frequency; OR, odds ratio; CI, confidence interval. 
 
 
Supplementary Table 8 | Samples included in preeclampsia subgroup analysis   
  N Offspring analysis N Maternal analysis 
  EO cases LO cases Controls EO cases LO cases Controls 
GOPEC 250 653 5,286 454 1,226 5,088 
deCODE* 380 1,183 372,012/371,209 393 1,223 136,400/137,522 
MoBa 170 824 887 297 1,089 930 
SSI       653 219 815 
Total 800 2,660 378,185 1,797 3,757 144,355 
EO, early onset preeclampsia; LO, late onset preeclampsia     













Supplementary Table 9 | Heritability of preeclampsia     
Per Cohort Heritability     
Region Type Cohort Heritability (SE) PH N % Cases 
Europe Maternal GOPEC 0.420 (0.050) 8.9E-17 6,971 26.9% 
Europe Maternal MoBa 0.192 (0.111) 0.082 2,270 59.6% 
Europe Maternal FINRISK 0.378 (0.187) 0.044 7,090 4.8% 
Central Asia Maternal Uzbekistan 0.699 (0.195) 0.00034 1,738 51.6% 
Central Asia Maternal Kazakhstan 0.432 (0.166) 0.0093 1,713 49.8% 
Europe Fetal GOPEC 0.193 (0.084) 0.022 6,266 16.0% 
Europe Fetal MoBa 0.266 (0.134) 0.048 1,864 53.0% 
Central Asia Fetal Uzbekistan 0.572 (0.201) 0.0044 1,702 50.4% 
Central Asia Fetal Kazakhstan 0.323 (0.167) 0.053 1,622 48.4% 
Fixed effect meta-analysis 
Region Type Heritability (95% CI) P Phet I
2 
Europe Maternal 0.381  (0.293,0.468) 1.4E-17 0.17 42.6 
Europe Fetal 0.213  (0.074,0.353) 0.0027 0.64 0 
Central Asia Maternal 0.544  (0.296,0.793) 1.7E-05 0.30 7.5 
Central Asia Fetal 0.425  (0.173,0.676) 0.00094 0.34 0 
Combined Maternal 0.399  (0.316,0.481) 2.6E-21 0.22 32.7 
Combined Fetal 0.263  (0.141,0.384) 2.4E-05 0.15 52.1 
SE, standard error. PH, P-Values are for a two-sided test that heritability differs from zero assuming that the 
GCTA heritability estimate is normally distributed with the specified standard error. CI, confidence interval. 
P, P-values are two sided and derived from fixed-effect meta-analysis of heritability. 
 
 
Supplementary Table 10 | Effect of preeclampsia variants on gestational hypertension  
          Preeclampsia Gestational hypertension   
Variant Chr Position EA/OA EAFEUR OR (95%CI) P OR (95%CI) P 
Annotated 
gene/cytoband 
Offspring meta-analysisa      
rs4769612 13 29,138,498 C/T 0.52 1.19 (1.13-1.24) 4.3E-14 1.04 (0.98-1.11) 0.21 FLT1/13q12 
Maternal meta-analysisb      
rs1918975 3 169,179,876 T/C 0.60 1.10 (1.07-1.14) 1.2E-08 1.02 (0.97-1.08) 0.46 MECOM/3q26 
rs1458038 4 81,164,723 T/C 0.33 1.11 (1.07-1.15) 1.2E-08 1.06 (0.99-1.13) 0.077 FGF5/4q21 
rs1421085 16 53,800,954 C/T 0.39 1.11 (1.07-1.15) 1.2E-09 1.09 (1.03-1.15) 1.7E-03 FTO/16q12 
rs259983 20 57,735,457 C/A 0.14 1.17 (1.11-1.23) 2.9E-10 1.05 (0.97-1.14) 0.22 ZNF831/20q13 
rs10774624 12 111,833,788 G/A 0.40 1.11 (1.07-1.15) 1.7E-08 1.13 (1.07-1.20) 3.7E-05 SH2B3/12q24 
Positions are based on Human genome version 19 (hg19), build 37. Chr, chromosome; EA, effect allele; OA, other allele; EAFEUR, risk 
allele frequency in European meta-analysis; OR, odds ratio; CI, confidence interval. 
aAssociation of fetal PE variant was tested in 4,275 offspring of gestational hypertension pregnancies and 381,740 controls 
bMaternal variants were tested in 3,428 gestational hypertension cases and 140,087 controls 
 




Supplementary Table 11| Genetic correlation between maternal preeclampsia and selected secondary traits     
  
Samples included in 
secondary trait 
analysis in deCODE 
data 
Genetic correlation with  
maternal preeclampsia 
meta-analysis of GOPEC, 
ALSPAC and MoBa data 
Samples included in 
secondary trait 
analysis in UKBB 
data 
Genetic correlation with 
maternal preeclampsia 
meta-analysis of deCODE, 
SSI and FINRISK data* 
Combined genetic 
correlation 
Secondary trait  N cases  N ctrl rg SE P-value  N cases  N ctrl rg SE P-value meta rg SE P-value 
Diastolic blood pressure 127,761 NA 0.49 0.116 2.4E-05 385,919 NA 0.36 0.079 3.7E-06 0.40 0.065 5.6E-10 
Systolic blood pressure 127,767 NA 0.37 0.100 2.0E-04 385,916 NA 0.33 0.069 2.2E-06 0.34 0.057 1.8E-09 
Hypertension 54,974 324,803 0.48 0.127 2.0E-04 77,566 331,087 0.37 0.079 3.0E-06 0.40 0.067 3.1E-09 
Coronary artery disease 37,878 320,415 0.17 0.123 0.16 10,860 397,707 0.37 0.090 4.4E-05 0.30 0.073 3.6E-05 
Ischemic stroke 9,878 369,026 0.00 0.250 1.00 3,299 405,268 0.26 0.323 0.43 0.10 0.208 0.63 
Venous Thromboembolism 4,967 343,276 0.45 0.190 1.8E-02 6,956 401,611 0.00 0.179 0.98 0.21 0.131 0.11 
Chronic kidney disease 3,870 358,181 0.27 0.394 0.49 4,537 404,030 0.03 0.191 0.89 0.07 0.164 0.67 
Type 2 diabetes 11,448 278,376 0.43 0.118 3.0E-04 22,389 386,178 0.29 0.078 2.0E-04 0.33 0.065 3.4E-07 
Body mass index (BMI) 82,556 NA 0.12 0.082 0.13 407,412 NA 0.13 0.056 2.1E-02 0.13 0.047 5.9E-03 
Birth weight of first child NA NA NA NA NA 178,241 NA -0.28 0.074 2.0E-04 -0.28 0.074 2.0E-04 
Asthma 16,307 351,734 -0.18 0.168 0.29 52,942 355,713 -0.05 0.071 0.46 -0.07 0.065 0.28 
Rheumatoid Arthritis 2,201 339,871 -0.01 0.318 0.98 4,047 404,518 0.09 0.183 0.64 0.06 0.150 0.69 
*Analysis of genetic correlation between birth weight and preeclampsia also includes MoBa data       










Supplementary Table 12 | Polygenic risk score analysis 
  Preeclampsia (1,703 cases and 74,678 controls) Gestational hypertension (1,553 cases and 75,109 controls) 
       Adjusted for HT-PRS       Adjusted for HT-PRS 
PRS phenotype P effect 95% CI P effect 95% CI P effect 95% CI P effect 95% CI 
Hypertension  1.2E-12 0.18 (0.13, 0.23)    2.1E-35 0.32 (0.27, 0.38)    
Type 2 diabetes  3.2E-03 0.07 (0.02, 0.12) 0.032 0.05 (0.00, 0.10) 0.16 0.04 (-0.01, 0.09) 1.00 0 (-0.05, 0.05) 
Body mass index 6.1E-03 0.07 (0.02, 0.12) 0.099 0.04 (-0.01, 0.09) 2.5E-05 0.11 (0.06, 0.16) 0.022 0.06 (0.01, 0.11) 
Coronary artery disease  4.1E-03 0.07 (0.02, 0.12) 0.091 0.04 (-0.01, 0.09) 3.9E-03 0.08 (0.02, 0.13) 0.44 0.02 (-0.03, 0.07) 
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166 (18) 109 (10) 
37 2608 
UK n=1875 (22.6-29.5) (34-39) (1863-3184) 




159 (13) 108 (9) 
39 3240 
UK n=146 (21.3-27.5) (37-40) (2710-3680) 




127 (10) 78 (7) 
40 3460 
UK n=6130 (20.4-23.9) (39-41) (3160-3780) 




151 (15) 102 (9) 
39 3294 
Iceland n=2618 (22.0-29.7) (37-40) (2730-3712) 




146 (14) 95 (9) 
39 3310 
Norway n=3074 (22.1-28.7) (37-40) (2754-3760) 




125 (11) 78 (8) 
40 3640 
Norway n=1599 (21.2-25.7) (40-41) (3300-3990) 
FINRISK Cases 29.3 
(6.0) 
64% NA NA NA 
39 2970 
Finland n=400 (36-40) (2365-3545) 
FINRISK Controls 27.7 
(5.4) 
95% NA NA NA 
40 3460 
Finland n=7805 (39-41) (3150-3780) 






Denmark n=872 (21.7-29.4) (31-39) (954-3066) 














160 (11) 105 (7) 
37 2840 







53% 25.7 119 (5) 78 (5) 40 3400 
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158 (12) 108 (8) 
37 2700 
Biobank n=2005 (22.3-27.0) (35-39) (2100-3200) 
Uzbekistan  








108 (7) 70 (6) 
39 3380 
Uzbekistan n=2006 (21.7-25.8) (39-40) (3100-3650) 
Gestational hypertension   
      




143 (12) 99 (8) 
40 3620 
Iceland n=2814 (21.5-28.2) (39-41) (3280-3988) 




149 (12) 95 (12) 
40 3440 
UK n=1252 (21.5-26.9) (39-41) (3100-3780) 




127.1 (9.9) 77.8 (7.0) 
40 3460 
UK n=6130 (20.4-23.9) (39-41) (3160-3780) 
Follow-up datasets        




166 (17) 109 (8) 
39 2825 
Finland n=678 (21.3-27.1) (35-39) (2180-3325) 




126 (12) 83 (8) 
40 3628 
Finland n=760 (20.8-25.9) (39-41) (3290-3960) 






Norway n=1134 (23.7-29.6) (38-41) (2760-3810) 






Denmark n=335 (22.1-29.6) (37-41) (2200-4100) 






Denmark n=1050 (21.0-26.2) (39-41) (2900-4100) 
*Mean and standard deviation 
      
†median and interquarSle range       
#The GOPEC, deCODE and HUNT studies used population controls     
NA: Not available        
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Supplementary Table 14 | Secondary traits from deCODE and UKBB  
  deCODE trait definition UKBB trait definition* 
Diastolic blood pressure 
BP measurements were obtained from Landspitali - the 
National University Hospital of Iceland in Reykjavik 
(LUH), the Primary Health Care Clinics of the Reykjavik 
area and at recruitment for deCODE studies, totaling 
measurements for 145,615 individuals with an average 
of 12 measurements per individual. 
Measurements were adjusted for sex, year of birth, age 
at measurement, measurement center and for use of 
drugs (by adding 10 mmHg to measured values for those 
taking blood pressure lowering drugs).  Blood pressure 
measurements were subsequently standardized to have 
a normal distribution.  
Diastolic blood pressure measurements (field 4079) 
adjusted for age at measurement, sex, year of birth, 40 
principle components and for use of drugs (by adding 10 
mmHg to measured values for those taking blood pressure 
lowering drugs). The adjusted trait values were then 
standardized using an inverse normal transform. 
Systolic blood pressure 
BP measurements were obtained from Landspitali - the 
National University Hospital of Iceland in Reykjavik 
(LUH), the Primary Health Care Clinics of the Reykjavik 
area and at recruitment for deCODE studies, totaling 
measurements for 145,615 individuals with an average 
of 12 measurements per individual. 
Measurements were adjusted for sex, year of birth, age 
at measurement, measurement center and for use of 
drugs (by adding 15 mmHg to measured values for those 
taking blood pressure lowering drugs).  Blood pressure 
measurements were subsequently standardized to have 
a normal distribution.  
Systolic blood pressure measurements (field 4080) adjusted 
for age at measurement, sex, year of birth, 40 principle 
components and for use of drugs (by adding 15 mmHg to 
measured values for those taking blood pressure lowering 
drugs). The adjusted trait values were then standardized 
using an inverse normal transform. 
Hypertension 
ICD10 codes I10.x,I11.x,O10.x, O11.x, I15.x (or the 
corresponding ICD9 codes) obtained from Landspitali - 
the National University Hospital of Iceland in Reykjavik 
(LUH) and  the Primary Health Care Clinics of the 
Reykjavik area.  
ICD10 code I10 in primary or secondary hospital diagnoses 
codes (fields 41202 and 41204). 
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Coronary artery disease ICD10 codes I20.0, I21.x, I22.X, I24.x, I25.x (or the 
corresponding ICD9 codes) from LUH or the Icelandic 
death registry.  
ICD10 codes I20.0, I21.x, I22.X, I24.x, I25.x, or operation 
proceedure codes indicative of CAD obtained from primary 
or secondary diagnoses codes a participant has had 
recorded across all their episodes in hospital.  
Ischemic stroke ICD9 codes 433.x,434.x,435.x,4371,438.x and ICD10 
codes I63.x,I693x from LUH. 
ICD10 codes I63.x and I69.3x obtained from primary or 
secondary diagnoses codes a participant has had recorded 
across all their episodes in hospital. 
Venous 
Thromboembolism 
ICD9 codes 415, 415.1, 451, 451.1, 451.2, 451.8, 451.9, 
453.1, 453.8, 459.1 and ICD10 codes I26, I26.9, I80, 
I80.1, I80.2, I80.3, I80.9, I82.1, I82.8, 187.0 obtained 
from LUH. 
ICD9 codes 415, 415.1, 451, 451.1, 451.2, 451.8, 451.9, 
453.1, 453.8, 459.1 and ICD10 codes I26, I26.9, I80, I80.1, 
I80.2, I80.3, I80.9, I82.1, I82.8, 187.0 obtained from primary 
or secondary diagnoses codes a participant has had 
recorded across all their episodes in hospital.  
Chronic kidney disease ICD10 code N18 ICD10 code N18 
Type 2 diabetes 
History of type 2 diabetes (self reported); HbA1C > 6.5; 
clinical diagnosis; ICD10 code E11; use of oral diabetes 
medication. Subjects with type 1 diabetes were 
excluded from the study. 
Type 2 diabetes based on ICD10 code E11 from primary or 
secondary hospital diagnosis (fields 41202 and 41204), on 
self-reported illnss codes 1220 and 1223 (field 20002) and 
on thouchscreen question on diabetes (field 2443). 
Individuals with diagnosis of gestational diabetes (ICD10 
code O244, self-reported illness code 1221 or thouchscreen 
question field 4041) or with type 1 diabetes (based on early 
insulin use, field 2986, or self-reported illness code 1222) 
were excluded. 
Body mass index (BMI) 
BMI information was available for 86,518 Icelandic 
individuals (Thorleifsson et.al. 2009 [PMID: 19079260] 
after excluding individuals not of Icelandic origin. The 
measurements were adjusted for gender, age, age2 and 
county of origin within Iceland, then averaged over 
multiple measurements for an individual, and 
standardized by using an inverse normal transform. 
Body mass index (field 21001) adjusted for age at 
measurment, sex, year of birth and 40 principle 
components. The adjusted trait values were then 
standardized using an inverse normal transform. 
Birth weight 
NA 
Self-reported birth weight of first child (field 2744) adjusted 
for year of birth and 40 principle components. The adjusted 





Icelandic asthma patients over 18 years of age were 
recruited who attended an asthma clinic or emergency 
rooom at the National University Hospital of Iceland or 
the Icelandic Medical Center (Laeknasetrid) during the 
years 1977 to 2017. Asthma diagnosis was based on a 
combination of physician‘s diagnosis and ICD10 
diagnosis, including anyone of J45.0, J45.1, J45.8, J45.9 
and J46 and/or self-reported by a positive reply to the 
question: “Has a doctor confirmed your asthma 
diagnosis“. 
Asthma in the UK Biobank was defined as ICD10 diagnoses 
in fields 41202 or 41204, including anyone of J45.0, J45.1, 
J45.8, J45.9 and J46 and/or self-reported by the non-cancer 
illness code, self-reported during verbal interview (data-
field 20002) with a code for asthma (1111). 
Rheumatoid Arthritis 
Diagnosis of rheumatoid arthritis based on fulfillment of 
classification criteria (ACR 1987 criteria) and/or ICD10 
codes M058, M059, M060, M068, M069 obtained from 
LUH or other rheumatology units in Iceland. 
Diagnosis of rheumatoid arthritis based on ICD10 codes 
M058, M059, M060, M068, M069 obtained from UK 
Biobank. 
*We included only individuals who were self-reported white British with similar genetic ancestry based on principal component analysis and with 





Supplementary Note 1: Construction of Central Asia Haplotype Reference Panel 
Extensive efforts have been made to provide reference panels of whole genome sequencing data from 
diverse populations through initiatives such as 1000Genomes, but Central Asian populations have not so 
far been included in these panels. Central Asia lies at the centre of the Silk Road, historic trading routes 
between Asia and Europe. The traditional nomadic lifestyle of much of the population, and repeated past 
invasions by surrounding powers, created a population of mixed ethnicity. During the Soviet era large 
numbers of Russians were resettled in Central Asia, and ethnic Russians made up a significant proportion 
of the population. The movement of ethnic Russians has reversed since the Central Asian republics 
gained independence in the early 1990s, and the two largest ethnic groups are now Kazakhs and Uzbeks. 
 
Whilst reference panels for genotype imputation are readily available for European populations, no such 
panel was available for the Kazakh and Uzbek populations of Central Asia. We therefore undertook 
whole genome sequencing (WGS) of 100 Kazakh and 100 Uzbek individuals, equally divided between 
males and females, recruited from Kazakhstan and Uzbekistan respectively. The ancestry of each Central 
Asian volunteer was determined by the ethnicity of all four grandparents. Of interest, Kazakhs are 
represented by three hoards, or zhus – older, middle and younger – and information about 
grandparental zhus was recorded for each Kazakh subject. 
 
Construction of Central Asia Haplotype Reference Panel 
 
200 Central Asian individuals (100 Kazak and 100 Uzbek) were whole genome sequenced at a coverage of 
approximately 4-5X. Variant calling discovered 11,870,850 single nucleotide polymorphisms (SNP) and 
1,013,884 indels including over 2 million variants not detected in 1000 Genomes Phase 1. Phased 
genotypes were used to create a haplotype reference panel, and genotype imputation performance was 
assessed in 1600 chip-genotyped subjects. Combining reference data from Central Asian WGS and 




A PCA analysis of the combined Central Asian WGS and 1000 Genomes Phase 3 (Europe, South Asia and 
East Asia) data indicates that the Kazakh and Uzbek populations are on a cline between East Asia and 
Europe with Uzbekistan exhibiting a greater affinity with Europe and South Asia (Supplementary Figure 
6).  Importantly, the analysis shows the two Central Asian populations clustering separately from any of 




We assessed the imputation quality using the internal IMPUTE2 leave one-out measurements of the 
squared correlation, , between the genotype dosage of 
directly genotyped variants vs the expected dosage of the corresponding imputed variants. We randomly 
selected 800 unrelated GWAS samples from each population and pre-phased each grouping of samples 
separately. The phased samples were then imputed into 4 different panels; 1000 Genomes Phase 3 + 
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Central Asia (1KGP3+CA), 1000 Genomes Phase 3 (1KGP3), 1000 Genomes Phase 1 (1KGP1) and Central 
Asia (CA). The imputation quality was assessed at sites that are present on both the chip and the 
intersection of tested reference panels. We find that both Uzbek and Kazakh samples exhibit better 
imputation quality across the full range of Central Asia allele frequencies with the combined panel 
(1KGP3+CA) than with any of the other panels (Supplementary Figure 7). Performance relative to allele 






This study was approved by the Central Commission on Ethics of the Republic of Kazakhstan, the National 
Ethics Committee of the Ministry of Health of the Republic of Uzbekistan, and the Medical School 
Research Ethics Committee of the University of Nottingham. Volunteers in each Central Asian country 
gave informed consent and provided an irreversibly anonymised sample of venous blood for DNA 
extraction.  
 
Subject recruitment and DNA Isolation 
 
200 Kazakh and 200 Uzbek subjects for WGS were recruited from healthy volunteers in Almaty, 
Kazakhstan, and Tashkent, Uzbekistan respectively. Only 100 of the 200 subjects from each country were 
selected for whole genome sequencing in order to enhance subject anonymity and protect the identity 
of the subjects whose genomes were sequenced.    
The grandparental ethnicity of all four grandparents of each subject was recorded to minimise ethnic 
admixture. Kazakhs belong to one of three Zhus (hordes); the Zhu of each subject was recorded at the 
time of recruitment and subjects were selected for WGS to account for the approximate composition of 
Zhus in Kazakhstan.  There were no corresponding ethnic strata in the Uzbek subjects who were 
therefore randomly selected.  Subjects selected for WGS were equally split between males and females 
for each country.  DNA was extracted in the country of origin and transferred to the Wellcome Trust 
Sanger Institute, UK, where it was subjected to quality control measures prior to sequencing. These 
included measurement of DNA concentration both by absorbance at 260nm/280nm and by the pico 
green method; gel electrophoresis to check for DNA degradation, and Sequenom genotyping at 30 SNPs, 
including four sex-specific variants. Samples which failed gender checks, or where Sequenom genotyping 
was unsuccessful at 10 or more SNPs, were not selected for WGS.  
 
Library Preparation and Sequencing 
 
Approximately 1ug genomic DNA for each subject was fragmented to an average size of 500 base pairs 
(bp) and subjected to DNA library creation using established Illumina paired-end protocols.  Adapter-
ligated libraries were amplified and indexed via PCR.  A portion of each library was used to create an 
equimolar pool comprising 8 indexed libraries.  Libraries were subjected to 100 base paired-end 
sequencing (HiSeq 2000; Illumina) according to manufacturer instructions. 
 
Alignment and assembly of short reads into whole genome sequence 
 
For each subject, several million short (~100 base) paired-end reads generated by Illumina HiSeq 2000 
sequencer were aligned with human reference sequence using the Sanger Institute sequencing pipeline 
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originally created for the 1000 Genomes Project (1000 Genomes Project Consortium 2010, 2012).    
Briefly, this involved the following steps: 
 
• Aligned to reference (1000 genomes hs37d5) using BWA  (bwa-0.5.10-mt)  
• Duplicates removed using Picard MarkDuplicates (picard-tools-1.72) 
• Merged to sample level BAMs 
• Realignment around known indels GATK RealignerTargetCreator and IndelRealigner 
• GATK BQSR (Base Quality Score Realignment) 
• Called using:  
o samtools-0.1.19 mpileup -EDVSp -C50 -m3 -F0.2 -d 40 
o samtools-0.1.19/bcftools/bcftools view -m 0.99 -vcgN 
• Variant filtering was carried out using VQSR GenomeAnalysisTK-2.7-2 
 
 
Construction of haplotype reference panels 
 
The Central Asia panel was created from the above filtered variants as follows: 
 
• The novel variants (i.e. those not in 1000 Genomes Phase 3 (1KGP3)) were merged with 1KGP3 
Biallelic and Multiallelic sites. 
 
• All variants were recalled using:  
GATK UnifiedGenotyper --genotyping_mode GENOTYPE_GIVEN_ALLELES. 
 
• The resulting genotype likelihoods were processed as follows: 
 
• An initial genotype refinement for 1KGP3 variants was carried out with Beagle (v4 (r1399.jar)) 
using the 1KGP3 panel (Europe+East Asia+South Asia groups only) downloaded from the Beagle 
website.  
 
• The genotype probabilities generated by this initial genotype refinement were then fixed as 
hard-called genotypes and merged with the genotype likelihoods of novel variants. 
 
• Beagle was then run again without a reference panel on this merged data-set in order to obtain 
refined calls for the novel variants. 
 
• The refined genotype probabilities for the novel variants were then extracted and merged with 
the refined genotype probabilities for 1KGP3 variants obtained from the first run of Beagle.  
 
• The Beagle vcf files were converted into Oxford gen format and then hard-called and filtered 
using plink2 (--hard-call-threshold 0.1 --geno 0.05) and saved again in Oxford gen format. 
 
• Shapeit (v2.r837) was then run with default parameters (again with no reference panel). 
 
The Central Asia + 1000 Genomes Phase 3 Reference Panel (1KGP3+CA) was constructed in 5Mb chunks 




Concordance of Chip Genotypes 
 
The WGS samples were also chip genotyped; 69 samples on Illumina OmniExpress 2.5.8 and 134 samples 
on Illumina OmniExpress (some samples were genotyped on both platforms).  Basic QC was carried out 
on these chip genotypes (call rate>98% and heterozygosity within 3 s.d. of the mean).  Supplementary 





The chip genotyped samples from Uzbekistan and Kazakhstan were separately QC’d using the following 
protocol.  Quality control analysis was conducted using PLINK (http://zzz.bwh.harvard.edu/plink/) and 
SMARTPCA. Briefly, the quality control included the following subject-level exclusion criteria: individual 
call rate <98%, heterozygosity >3 s.d. from the mean; any of the first three HapMap (based on CEU, YRI, 
CHB, JPT and GIH populations) principal axes of variation >4 s.d. from the mean; and sex mismatch. 
Related individuals (identity by descent (IBD) > 0.1) with the lowest call rates were preferentially 
removed. The variant-level exclusion criteria were as follows: call rate <98%; exact Hardy–Weinberg 
equilibrium P < 1 × 10−6; minor allele frequency (MAF) <1%; and non-random missingness of uncalled 
genotypes (plink–test-mishap) with Bonferroni-corrected P < 0.05.  
 
From each of the above datasets 800 female samples that passed the above subject-level QC were 
selected and 123,250 chromosome 1 chip genotyped SNPs that were present in both KAZ and UZB post 
QC datasets.  
 
The samples were pre-phased without a reference panel using shapeit2 (v2.r727) with default 
parameters except ( --effective-size 12000).  The samples were then imputed with impute2 (v2.3.1) with 




The combined reference panel was first converted to VCF format using “bcftools convert -H” and then 
converted to plink format.  The resulting variants were filtered to include variants with MAF>0.05 and 
pruned so that no variants within a window of 1Mb exhibit a pairwise LD  > 0.1 
(plink --indep-pairwise 1000kb 100 0.1).  The first 10 Principal Components were then calculated using 









 Supplementary Note 2: Correcting for Population Stratification in EMIM 
Introduction 
In [1] a method is introduced for inferring Maternal, Fetal, Imprinting and Maternal-Fetal Interaction 
effects from family genotype data. This method, EMIM, fits a genetic model using a multinomial 
likelihood model for the possible family genotype combinations constrained by Mendelian inheritance. 
Taking advantage of recent improvements in statistical haplotype phasing improvements a recent 
extension to the method [2] resolves heterozygous genotype cells to improve inference of parent of 
origin effects.  
One difficulty in using EMIM in mildly heterogeneous populations is that it does not provide a means to 
control for population stratification. Here we present an extension that incorporates cohort indicator 
variables and ancestry principal components as covariates into the method. We provide an R package 
implementation of the method (remim).  
Methods 
Following the notation in [1] we assume the following model for penetrance. Let A2 be the risk allele 
with allele frequency  (alternate allele A1 has allele frequency  = 1-)  
• 	 copies of A2 in the child multiplies penetrance by 
   
• 	 copies of A2 in the mother multiplies penetrance by   
• 	 paternally transmitted copies A2 multiplies penetrance by    
• 	 maternally transmitted copy A2 multiplies penetrance by   
• 	 maternal copies of A2 and j fetal copies A2 multiplies penetrance by , 
This gives the following equation for the penetrance:  
|, , ,   = 
 ! !,  !           (1) 
Where  = "
 , ,  ,  , , , # and ,  and  are the counts of the maternal untransmitted, 
maternal transmitted and paternal transmitted risk alleles and  is the disease prevalence. 
The central equation in [1] is:  
, , | =  $|!,, )
∑  ($|!,, )&',&(,)(
(, , )           (2) 
Here we assume random mating, so that we can write:  
, ,  = ! 1 − +,!                          (3) 
In the case where we have genotype data but are unable to infer transmitted and untransmitted alleles 
(e.g for sparsely genotyped datasets) it is necessary to sum over values of ,  and  that are 
consistent with the genotype data:  
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-, -.| = ∑ , , |!,, :!01, 012        (4) 
-, -., -3| = ∑ , , |!,, :!01, 012,  !014      (5) 
 
In practice it is necessary to partition the samples into maximal family units of various types: Case Trios, 
Case Duos, Case Mothers, Case Fathers, Case Offspring, Control Parents, Control Duos and Controls. 
Summing over these independent family units gives the following equation for the log likelihood of the 
observed allele counts/genotypes:  
ℒ67, 68, 98, 97, :;, :<, :6|= =  > log , , , |, 
BCDE FGD
 
                                                                + > log , , |, )
BCDE $IGD
                     
                                                                + > log -.|, )
BCDE J44D FK1
 
                                                                + > log -|, 
BCDE LGMNEFD
 
                                                                + > log -O|, 
BGKMFGPD
 
               (6) 
 
The parameters  are then fitted by maximising the above likelihood and statistical significance is 
assessed by likelihood ratio tests on nested models or by estimating standard errors in the usual way 
using the inverse Hessian matrix. Note that the above model fits a single population allele frequency in 
the above process.  
Here, rather than fitting a single allele frequency, we propose modelling individual specific 
genotype/allele probabilities (allele frequency) using a logit transform of the weighted sum of continuous 
covariates:  





        (7) 





        (8) 
 
Where .and . are maternal and paternal covariates respectively (e.g. principal components or 
cohort indicator variable). In the case of Duos the missing parent covariate can be estimated by assuming 
that the child covariates ci(c) (available by assumption) are the average of parental covariates. For lone 
39 
 
cases (Mothers, Fathers or Offspring) we do not necessarily have values for the missing parents. Under 
these circumstances we are forced to either remove the samples or to make an assortative mating 
assumption and set unknown covariates to the same value as the sampled family member. For lone 
controls the covariates of the individual sample are sufficient.  
We incorporated these new variables into = as   = "
 , ,  ,  , ,W# so that the β coefficients are 
jointly estimated with the parameters of the EMIM genetic model by maximising the composite log-
likelihood for the set of parameters:  
ℒ67, 68, 98, 97, :;, :<, :6|, ; =  > log , , , |, , ;
BCDE FGD
 
                                                                + > log , , |, , ;)
BCDE $IGD
                     
                                                                + > log -.|, , ;)
BCDE J44D FK1
 
                                                                + > log -|, , ;
BCDE LGMNEFD
 
                                                                + > log -O|, , ;
BGKMFGPD
 
               (9) 
We now set out the formulae for the probabilities in the above.  
For Mother-Child Duos we have:  
|, , ,  = 
 !XY,Z + Y,[XY ,Z + Y , [!,  !            (10) 
, , |, , ; = |, , , 
exp _ ∑ . WK0 `
a1 + exp _∑ . WK0 `b
exp _ +  ∑ .WK0 `
a1 + exp _∑ .WK0 `b
  
              (11) 
For Trios we have:  




      (12) 
 
For a Control Trios we have:  





cde_! ∑ 2R&fRTRUV `
acde_∑ 2R
&fRTRUV `b




In the case where we only have genotype data available we can marginalise over mU, mT, pU and pT.  So, 
for Case Mothers we have: 
-|, , ; = ∑ ∑ , , |, , ;h!,:!01i                    (14)  
For Case Offspring: 
-.|, , ; = ∑ ∑ , , |, , ;h, : 012i!      (15) 
For Controls: 
  
-O|, , ; = cde"1j ∑ 2RfRTRUV #Xcde"∑ 2RfRTRUV #[g        (16) 
Where . represent the ith principal component/indicator variable of the control individual. 
Discussion 
The extension to include cohort indicator variables and principal components extends the scope of the 
method allowing the joint analysis of multiple cohorts and/or genetically heterogeneous populations.  
The cost of considering continuous covariates is that individuals must be included separately in the 
likelihood equation rather than grouped into cells containing the same genotype combinations.  This 
makes the approach less computationally efficient and so less appropriate for analysing whole genome 
data.  
We provide a R based implementation (remim) where we have made of use of explicit expressions for 
both the likelihood and likelihood gradient to facilitate the rapid convergence of R’s “optim” function 
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